miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression
文献类型：期刊论文
| 作者 | Mu, WJ; Hu, CB; Zhang, HB; Qu, ZQ; Cen, J; Qiu, ZX; Li, C; Ren, HZ; Li, YX; He, XH |
| 刊名 | CELL RESEARCH
 |
| 出版日期 | 2015 |
| 卷号 | 25期号:4页码:477-495 |
| 关键词 | liver cancer kidney cancer miR-27b drug resistance p53 CYP1B1 |
| 通讯作者 | Hui, LJ (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China.,njsxl2000@163.com ; ljhui@sibcb.ac.cn |
| 英文摘要 | Liver and kidney cancers are notorious for drug resistance. Due to the complexity, redundancy and interpatient heterogeneity of resistance mechanisms, most efforts targeting a single pathway were unsuccessful. Novel personalized therapies targeting multiple essential drug resistance pathways in parallel hold a promise for future cancer treatment. Exploiting the multitarget characteristic of microRNAs (miRNAs), we developed a new therapeutic strategy by the combinational use of miRNA and anticancer drugs to increase drug response. By a systems approach, we identified that miR-27b, a miRNA deleted in liver and kidney cancers, sensitizes cancer cells to a broad spectrum of anticancer drugs in vitro and in vivo. Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in patients carrying p53-wild-type or CYP1B1-high signature. Together, we propose that miR-27b synergizes with anticancer drugs in a defined subgroup of liver and kidney cancer patients. |
| 学科主题 | Cell Biology |
| 类目[WOS] | Cell Biology |
| 关键词[WOS] | RENAL-CELL CARCINOMA ; HEPATOCELLULAR-CARCINOMA ; TARGETING MICRORNAS ; EXPRESSION PROFILES ; CLINICAL-TRIALS ; CANCER-THERAPY ; BREAST-CANCER ; CYCLIN-G ; RESISTANCE ; KNOWLEDGE |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000353917200006 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/49]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Mu, WJ,Hu, CB,Zhang, HB,et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression[J]. CELL RESEARCH,2015,25(4):477-495. |
| APA | Mu, WJ.,Hu, CB.,Zhang, HB.,Qu, ZQ.,Cen, J.,...&Hui, LJ.(2015).miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.CELL RESEARCH,25(4),477-495. |
| MLA | Mu, WJ,et al."miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression".CELL RESEARCH 25.4(2015):477-495. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。